Skin Analytics secures EU approval for smartphone-based cancer screening

The platform builds upon six years of deployment within the UK's National Health Service, where the underlying DERM AI has evaluated over 230,000 patients and identified more than 20,000 cases of skin cancer. By moving this diagnostic capability from specialized hospital hardware to everyday mobile devices, the company aims to eliminate traditional barriers to early detection, such as long wait times and the requirement for in-person specialist appointments.

Unlike consumer-grade skin apps, DERM Zero provides definitive clinical decisions without requiring secondary review by a dermatologist. The system functions by analyzing high-resolution images of lesions captured by the user, instantly flagging suspicious cases for medical intervention or clearing benign ones. Clinical data indicates the software maintains a 98% cancer detection rate, performing on par with face-to-face specialist assessments. Following its debut in Amsterdam, Skin Analytics plans to integrate the technology into European healthcare pathways starting in June 2026, shifting the focus of cancer screening toward primary care and community settings.